Ultragenyx Pharmaceutical Inc. Shareholders Can Join Class Action Lawsuit Over Significant Losses
In a significant development for investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), the law firm Robbins Geller Rudman & Dowd LLP has announced that individuals who purchased or acquired common stock in the company between August 3, 2023, and December 26, 2025, have the opportunity to lead a class action lawsuit. This lawsuit is rooted in allegations of violations against the Securities Exchange Act of 1934 by Ultragenyx and certain executives.
The class action, captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), seeks to hold the company accountable for misleading statements regarding its product, setrusumab, intended for treating Osteogenesis Imperfecta (OI). The crux of the lawsuit lies in claims that Ultragenyx falsely portrayed its clinical trials' potential and downplayed risks associated with its research. Specifically, the lawsuit details how Ultragenyx created an illusion of possessing reliable information about the effects of their treatment on patients while not adequately addressing the possibility of study failures.
The allegations against Ultragenyx intensified following the release of troubling news regarding the Phase III Orbit study on July 9, 2025. The study failed to achieve the expected statistical significance, resulting in a drastic decrease in Ultragenyx's stock price—over 25%—immediately following the announcement. Moreover, the subsequent news release on December 29, 2025, further exacerbated investor losses, revealing even more disappointing results from both the Orbit and Cosmic studies, leading to an additional drop of over 42% in stock value.
Investors who experienced significant losses during the defined Class Period should act quickly, as they have until April 6, 2026, to seek appointment as the lead plaintiff in the class action case. This legal position is typically granted to the investor who demonstrates the highest financial stake in the resulting litigation while also being representative of the class. A lead plaintiff will make strategic decisions on behalf of all class members and has the authority to choose a law firm to represent their interests.
For those investors interested in contributing to this important case, information can be provided online, or they may contact attorney J.C. Sanchez at Robbins Geller directly via phone or email for further assistance.
Robbins Geller is recognized as one of the premier law firms specializing in complex class actions related to securities fraud and shareholder rights litigation. The firm has an impressive history of recovering significant financial settlements for investors—711 million dollars in 2025 alone, marking their fourth #1 ranking in the top class action firms over the past five years. Their expertise in the field ensures that investors who choose to participate in the class action will have access to seasoned legal professionals committed to navigating the complexities of securities litigation.
Overall, this class action lawsuit offers a vital opportunity for Ultragenyx investors to potentially recover losses stemming from critical disclosures and product-related disappointments. Investors are urged to assess their options and consider joining this collective legal action as they seek accountability and restitution for their financial grievances.
Overview of the Class Action
The class action, captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), seeks to hold the company accountable for misleading statements regarding its product, setrusumab, intended for treating Osteogenesis Imperfecta (OI). The crux of the lawsuit lies in claims that Ultragenyx falsely portrayed its clinical trials' potential and downplayed risks associated with its research. Specifically, the lawsuit details how Ultragenyx created an illusion of possessing reliable information about the effects of their treatment on patients while not adequately addressing the possibility of study failures.
The allegations against Ultragenyx intensified following the release of troubling news regarding the Phase III Orbit study on July 9, 2025. The study failed to achieve the expected statistical significance, resulting in a drastic decrease in Ultragenyx's stock price—over 25%—immediately following the announcement. Moreover, the subsequent news release on December 29, 2025, further exacerbated investor losses, revealing even more disappointing results from both the Orbit and Cosmic studies, leading to an additional drop of over 42% in stock value.
How to Participate in the Class Action
Investors who experienced significant losses during the defined Class Period should act quickly, as they have until April 6, 2026, to seek appointment as the lead plaintiff in the class action case. This legal position is typically granted to the investor who demonstrates the highest financial stake in the resulting litigation while also being representative of the class. A lead plaintiff will make strategic decisions on behalf of all class members and has the authority to choose a law firm to represent their interests.
For those investors interested in contributing to this important case, information can be provided online, or they may contact attorney J.C. Sanchez at Robbins Geller directly via phone or email for further assistance.
About Robbins Geller Rudman & Dowd LLP
Robbins Geller is recognized as one of the premier law firms specializing in complex class actions related to securities fraud and shareholder rights litigation. The firm has an impressive history of recovering significant financial settlements for investors—711 million dollars in 2025 alone, marking their fourth #1 ranking in the top class action firms over the past five years. Their expertise in the field ensures that investors who choose to participate in the class action will have access to seasoned legal professionals committed to navigating the complexities of securities litigation.
Overall, this class action lawsuit offers a vital opportunity for Ultragenyx investors to potentially recover losses stemming from critical disclosures and product-related disappointments. Investors are urged to assess their options and consider joining this collective legal action as they seek accountability and restitution for their financial grievances.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.